Amphastar Pharma (AMPH) Tops Q4 EPS by 33c

Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of $0.73, $0.33 better than the analyst estimate of $0.40. Revenue for the quarter came in at $135 million versus the consensus estimate of $127.25 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• FDA approves Padcev plus Keytruda for muscle-invasive bladder cancer
• UBS Reiterates Buy Rating on Dollar Tree (DLTR)